Genmab (HuMax-IL8) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Genmab (HuMax-IL8) General Information

Description

An antibody license for treatment of selected cancers. The asset is a high-affinity, fully human antibody directed towards IL-8. IL-8 has been shown to be involved in several aspects of tumor development, including tumor spread (metastasis), cancer stem cell renewal and tumor immunosuppression.

Contact Information

Formerly Known As
HuMax-Inflam/MDX-018
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Copenhagen
  • Denmark
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Corporate Office
  • Copenhagen
  • Denmark

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genmab (HuMax-IL8) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Genmab (HuMax-IL8)‘s full profile, request access.

Request a free trial

Genmab (HuMax-IL8) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Genmab (HuMax-IL8)‘s full profile, request access.

Request a free trial

Genmab (HuMax-IL8) FAQs

  • Where is Genmab (HuMax-IL8) headquartered?

    Genmab (HuMax-IL8) is headquartered in Copenhagen, Denmark.

  • What industry is Genmab (HuMax-IL8) in?

    Genmab (HuMax-IL8)’s primary industry is Buildings and Property.

  • Is Genmab (HuMax-IL8) a private or public company?

    Genmab (HuMax-IL8) is a Private company.

  • What is Genmab (HuMax-IL8)’s current revenue?

    The current revenue for Genmab (HuMax-IL8) is .

  • Who are Genmab (HuMax-IL8)’s investors?

    Genmab has invested in Genmab (HuMax-IL8).

  • When was Genmab (HuMax-IL8) acquired?

    Genmab (HuMax-IL8) was acquired on 30-May-2012.

  • Who acquired Genmab (HuMax-IL8)?

    Genmab (HuMax-IL8) was acquired by Cormorant Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process